Physician profile
Roberto Tongson
NPI 1467450676
$5,743.97
in general payments reported to CMS, 2019-2025
23 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $591 · 2021: $970 · 2022: $1,007 · 2023: $729 · 2024: $581 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,430.23 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,334.60 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $960.35 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $574.41 | 2021-2024 | Vraylar |
| Amgen INC. | $545.44 | 2022-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $353.43 | 2020-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $328.97 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $289.20 | 2019-2022 | |
| Dexcom, INC. | $227.56 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.43 | 2021-2023 | Xifaxan |
| Allergan, INC. | $168.79 | 2019-2020 | |
| Glaxosmithkline, LLC. | $103.75 | 2019-2021 | |
| Lilly USA, LLC | $98.64 | 2020-2023 | Emgality, Jardiance |
| Mylan Specialty L.P. | $96.09 | 2021-2023 | Yupelri |
| Harmony Biosciences LLC | $81.82 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $76.85 | 2020-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $74.22 | 2022 | |
| Pfizer INC. | $65.07 | 2020-2025 | |
| Corcept Therapeutics | $52.46 | 2025 | Korlym |
| Philips North America LLC | $43.80 | 2019-2020 | |
| Radius Health, INC. | $27.60 | 2020 | |
| Exact Sciences Corporation | $24.93 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $21.68 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $20.88 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Tongson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.